In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue ...
Bio-Techne is down 28.6% since the beginning of the year, and at $51.01 per share, it is trading 36.5% below its 52-week high of $80.36 from September 2024. Investors who bought $1,000 worth of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback